Update under Regulation 30 read with Para A Part A of Schedule III of SEBI (Listing Obligations and Dicsloure Requirements) Regulations, 2015
MEDPLUS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Optival Health Solutions Private Limited, a subsidiary of Medplus Health Services, has received two drug license suspension orders from authorities. The first order, from the Assistant Director, Drugs Control Administration, Siddipet, Telangana, suspends the license of a store on Market Road Narsapur for two days, with a potential revenue loss of Rs 0.18 lakh. The second order, from the Assistant Director, Drugs Control Administration, Shimoga Circle, Karnataka, suspends the license of a store at Vinobha Nagar for five days, with a potential revenue loss of Rs 4.85 lakh. Both suspensions were issued under Rule 65 of the Drugs and Cosmetics Act, 1940 and the Drugs and Cosmetics Rules, 1945. The orders were received on 20 May 2026, and the company disclosed this update on 21 May 2026 as per SEBI LODR requirements.
The combined quantifiable revenue impact is approximately Rs 5.03 lakh across two stores, which is relatively small for a company of Medplus's scale. However, the regulatory action — even if temporary — could raise concerns about compliance processes at the subsidiary level, particularly given it affects pharmacy retail operations, a core business activity.